"V体育ios版" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2014 Nov 6;19(11):18179-91.
doi: 10.3390/molecules191118179.

"VSports最新版本" Icariin is a PPARα activator inducing lipid metabolic gene expression in mice

Yuan-Fu Lu  1 , Yun-Yan Xu  2 , Feng Jin  3 , Qin Wu  4 , Jing-Shan Shi  5 , Jie Liu  6
Affiliations

Icariin is a PPARα activator inducing lipid metabolic gene expression in mice

Yuan-Fu Lu et al. Molecules. .

Abstract

Icariin is effective in the treatment of hyperlipidemia. To understand the effect of icariin on lipid metabolism, effects of icariin on PPARα and its target genes were investigated. Mice were treated orally with icariin at doses of 0, 100, 200, and 400 mg/kg, or clofibrate (500 mg/kg) for five days. Liver total RNA was isolated and the expressions of PPARα and lipid metabolism genes were examined. PPARα and its marker genes Cyp4a10 and Cyp4a14 were induced 2-4 fold by icariin, and 4-8 fold by clofibrate. The fatty acid (FA) binding and co-activator proteins Fabp1, Fabp4 and Acsl1 were increased 2-fold. The mRNAs of mitochondrial FA β-oxidation enzymes (Cpt1a, Acat1, Acad1 and Hmgcs2) were increased 2-3 fold VSports手机版. The mRNAs of proximal β-oxidation enzymes (Acox1, Ech1, and Ehhadh) were also increased by icariin and clofibrate. The expression of mRNAs for sterol regulatory element-binding factor-1 (Srebf1) and FA synthetase (Fasn) were unaltered by icariin. The lipid lysis genes Lipe and Pnpla2 were increased by icariin and clofibrate. These results indicate that icariin is a novel PPARα agonist, activates lipid metabolism gene expressions in liver, which could be a basis for its lipid-lowering effects and its beneficial effects against diabetes. .

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effects of Icariin (ICA) on expression of PPARα and PPARα marker enzymes. Data are expressed as mean ± SEM (n = 5). * Significantly different from CMC-treated mice (p < 0.05).
Figure 2
Figure 2
Effects of Icariin (ICA) on expression of fatty acid binding proteins and coactivators. Data are expressed as mean ± SEM (n = 5). * Significantly different from CMC-treated mice (p < 0.05).
Figure 3
Figure 3
Effects of Icariin (ICA) on expression of mitochondrial fatty acid β-oxidation enzymes. Data are expressed as mean ± SEM (n = 5). * Significantly different from CMC-treated mice (p < 0.05).
Figure 4
Figure 4
Effects of Icariin (ICA) on expression of peroxisome fatty acid β-oxidation enzymes. Data are expressed as mean ± SEM (n = 5). * Significantly different from CMC-treated mice (p < 0.05).
Figure 5
Figure 5
Effects of Icariin (ICA) on Expression of lipogenesis enzymes. Data are expressed as mean ± SEM (n = 5). * Significantly different from CMC-treated mice (p < 0.05).
Figure 6
Figure 6
Effects of Icariin (ICA) on expression of lipolytic enzymes. Data are expressed as mean ± SEM (n = 5). * Significantly different from CMC-treated mice (p < 0.05).
See this image and copyright information in PMC

References

    1. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha (PPARalpha): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205:1–8. doi: 10.1016/j.atherosclerosis.2009.03.008. - DOI - PubMed
    1. Seok H., Cha B.S. Refocusing peroxisome proliferator activated receptor-α: A new insight for therapeutic roles in diabetes. Diabetes Metab. J. 2013;37:326–332. doi: 10.4093/dmj.2013.37.5.326. - DOI - PMC - PubMed
    1. Duval C., Müller M., Kersten S. PPARalpha and dyslipidemia. Biochim. Biophys. Acta. 2007;1771:961–971. doi: 10.1016/j.bbalip.2007.05.003. - DOI - PubMed
    1. Costet P., Legendre C., Moré J., Edgar A., Galtier P., Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 1998;273:29577–29585. doi: 10.1074/jbc.273.45.29577. - "V体育平台登录" DOI - PubMed
    1. Abdelmegeed M.A., Yoo S.H., Henderson L.E., Gonzalez F.J., Woodcroft K.J., Song B.J. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J. Nutr. 2011;141:603–610. doi: 10.3945/jn.110.135210. - DOI - PMC - PubMed

Publication types

MeSH terms (V体育安卓版)